These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 16453395)

  • 61. Editorial overview: from Vioxx to Luckenbach: drug discovery at a crossroads.
    Williams M
    Curr Opin Investig Drugs; 2005 Jan; 6(1):17-20. PubMed ID: 15675599
    [No Abstract]   [Full Text] [Related]  

  • 62. Court hears how drug giant Merck tried to "neutralise" and "discredit" doctors critical of Vioxx.
    Moynihan R
    BMJ; 2009 Apr; 338():b1432. PubMed ID: 19349350
    [No Abstract]   [Full Text] [Related]  

  • 63. How honest can a medical journal be?
    Groves T
    Aust N Z J Obstet Gynaecol; 2006 Feb; 46(1):2-3. PubMed ID: 16441685
    [No Abstract]   [Full Text] [Related]  

  • 64. Painkiller verdict shows mistrust of Merck.
    Khamsi R
    Nature; 2005 Aug; 436(7054):1070. PubMed ID: 16121136
    [No Abstract]   [Full Text] [Related]  

  • 65. Observational studies and the withdrawal of rofecoxib.
    Watson DJ; Santanello NC
    Pharmacoepidemiol Drug Saf; 2006 Mar; 15(3):199-201; author reply 203-5. PubMed ID: 16508998
    [No Abstract]   [Full Text] [Related]  

  • 66. The preacher who's raising hell with Merck.
    Parloff R
    Fortune; 2005 Aug; 152(3):20. PubMed ID: 16097189
    [No Abstract]   [Full Text] [Related]  

  • 67. Drug safety: are we making progress?: comment on "pooled analysis of rofecoxib placebo-controlled clinical trial data".
    Luepker RV
    Arch Intern Med; 2010 Jan; 170(2):202. PubMed ID: 20101016
    [No Abstract]   [Full Text] [Related]  

  • 68. More on JAMA's policy on industry sponsored studies.
    Rothman KJ; Evans S
    BMJ; 2006 Feb; 332(7539):489. PubMed ID: 16497774
    [No Abstract]   [Full Text] [Related]  

  • 69. [The CLASS study and its scientific statement. Ethical publishing rules neglected].
    Wollheim FA
    Lakartidningen; 2002 Oct; 99(40):3934-5. PubMed ID: 12422748
    [No Abstract]   [Full Text] [Related]  

  • 70. The effect of conflict of interest on biomedical research and clinical practice guidelines: can we trust the evidence in evidence-based medicine?
    Abramson J; Starfield B
    J Am Board Fam Pract; 2005; 18(5):414-8. PubMed ID: 16148253
    [No Abstract]   [Full Text] [Related]  

  • 71. Comparison of schizophrenia drugs often favors firm funding study.
    Vendantam S
    Washington Post; 2006 Apr; ():A1, A6. PubMed ID: 16856276
    [No Abstract]   [Full Text] [Related]  

  • 72. Merck Sharp and Dohme versus Laporte.
    Honig P
    Lancet; 2004 Mar; 363(9414):1079-80. PubMed ID: 15051302
    [No Abstract]   [Full Text] [Related]  

  • 73. Scientific harassment by pharmaceutical companies: time to stop.
    Hailey D
    CMAJ; 2000 Jan; 162(2):212-3. PubMed ID: 10674057
    [No Abstract]   [Full Text] [Related]  

  • 74. Worrisome ailment in medicine: misleading journal articles; editors demand more data to ensure full disclosure of drug risks, trial gaps; Sarbanes-Oxley for professors.
    Mathews AW
    Wall St J (East Ed); 2005 May; ():A1, A9. PubMed ID: 15966125
    [No Abstract]   [Full Text] [Related]  

  • 75. NEJM stands by its criticism of Vioxx study.
    Tanne JH
    BMJ; 2006 Mar; 332(7540):505. PubMed ID: 16513694
    [No Abstract]   [Full Text] [Related]  

  • 76. The ADVANTAGE seeding trial: a review of internal documents.
    Hill KP; Ross JS; Egilman DS; Krumholz HM
    Ann Intern Med; 2008 Aug; 149(4):251-8. PubMed ID: 18711155
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Reporting bias in industry-supported medication trials presented at the American Psychiatric Association meeting.
    Sen S; Prabhu M
    J Clin Psychopharmacol; 2012 Jun; 32(3):435. PubMed ID: 22561482
    [No Abstract]   [Full Text] [Related]  

  • 78. Merck to pay $5bn in rofecoxib claims.
    Charatan F
    BMJ; 2007 Nov; 335(7628):1011. PubMed ID: 18006982
    [No Abstract]   [Full Text] [Related]  

  • 79. Correspondence (letter to the editor): Need for advice.
    Grass G; Mäder K
    Dtsch Arztebl Int; 2010 Sep; 107(38):672; author reply 673-4. PubMed ID: 20953261
    [No Abstract]   [Full Text] [Related]  

  • 80. Arguments against publishing tobacco funded research also apply to drug industry funded research.
    Smith R
    BMJ; 2013 Nov; 347():f6732. PubMed ID: 24252687
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.